Teresa Gabriela Krieger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Teresa Gabriela Krieger has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
- Angelika Eggert
Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany
13 shared publications - Annette Künkele
Department of Pediatric Oncology and Hematology, Charité – Universitätsmedizin Berlin, Berlin, Germany
13 shared publications - Annika Lehmann
Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
13 shared publications - Anton George Henssen
Department of Pediatric Hematology and Oncology, Charité-Universitätsmedizin Berlin, Berlin, Germany
13 shared publications - Arend Koch
Department of Neuropathology Charité‐Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin Berlin Germany
13 shared publications - Bartolomeo Bosco
Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany
13 shared publications
Latest Publications
- Open Access
Tumor-versus-non-tumor T cell enrichment supported by single-cell and spatial phenotyping enables antigen-agnostic prioritization of candidate tumor-reactive TCRs
Introduction: Tumor-reactive T cell receptors (TCRs) are promising candidates for the manufacturing of safe and effective adoptive TCR-T cell therapies, but their efficient identification remains a major challenge. We previously established an antigen-agnostic TCR-repertoire analysis workflow that prioritizes candidate TCRs based on intratumoral clonal expansion and high tumor-to-non-tumor (T/N) frequency ratios. Here, we investigated whether T/N-selected clonotypes show independent transcriptional and spatial features consistent with tumor association. Methods: Bulk and single-cell TCR repertoire sequencing of paired tumor and adjacent non-tumor tissues was used to identify clonotypes with high T/N ratios across 15 cancer cases, comprising six non-small cell lung cancers, five pancreatic cancers, two breast cancers, and two colorectal cancers. Candidate clonotypes were further characterized by paired single-cell TCR and gene expression profiling and, in two PDAC cases, by Xenium spatial transcriptomics to assess their cellular phenotype, spatial localization, and proximity to malignant cells. Results: High T/N ratios consistently marked T cell clonotypes with features of tumor reactivity across the studied solid tumor entities. The analysis included Cluster-A, a lead T cell cluster comprising highly similar TCRs shared among 14 HLA-A*02:01-positive patients in the present cohort. Cluster-A clonotypes were consistently enriched in tumor relative to matched non-tumor tissue, and previous functional studies demonstrated tumor recognition by Cluster-A members. In a focused analysis of a pancreatic cancer case, Cluster-A CD8 + T cells were selectively detected in tumor tissue, preferentially localized near malignant epithelial cells, and displayed an antigen-experienced effector-memory phenotype with prominent expression of granzymes A and K (GZMA/GZMK). Importantly, in another PDAC case that lacked Cluster-A clonotypes, these features extended to independent clonotypes, revealing a continuous tumor-association axis in which increasing T/N ratios were associated with progressively closer localization to malignant cells and increased GZMA/GZMK expression. Thus, repertoire enrichment, spatial tumor proximity, and effector-associated transcriptional states converged across independent tumor-enriched clonotypes. Outlook: These findings support the T/N ratio as a robust primary criterion for identifying candidate tumor-reactive TCRs. Integration of single-cell and spatial transcriptomics provides supporting biological evidence of tumor association and a framework for prioritizing therapeutic TCR candidates when functional validation is limited.
Open AccessTumor-versus-non-tumor T cell enrichment supported by single-cell and spatial phenotyping enables antigen-agnostic prioritization of candidate tumor-reactive TCRs
Introduction: Tumor-reactive T cell receptors (TCRs) are promising candidates for the manufacturing of safe and effective adoptive TCR-T cell therapies, but their efficient identification remains a major challenge. We previously established an antigen-agnostic TCR-repertoire analysis workflow that prioritizes candidate TCRs based on intratumoral clonal expansion and high tumor-to-non-tumor (T/N) frequency ratios. Here, we investigated whether T/N-selected clonotypes show independent transcriptional and spatial features consistent with tumor association. Methods: Bulk and single-cell TCR repertoire sequencing of paired tumor and adjacent non-tumor tissues was used to identify clonotypes with high T/N ratios across 15 cancer cases, comprising six non-small cell lung cancers, five pancreatic cancers, two breast cancers, and two colorectal cancers. Candidate clonotypes were further characterized by paired single-cell TCR and gene expression profiling and, in two PDAC cases, by Xenium spatial transcriptomics to assess their cellular phenotype, spatial localization, and proximity to malignant cells. Results: High T/N ratios consistently marked T cell clonotypes with features of tumor reactivity across the studied solid tumor entities. The analysis included Cluster-A, a lead T cell cluster comprising highly similar TCRs shared among 14 HLA-A*02:01-positive patients in the present cohort. Cluster-A clonotypes were consistently enriched in tumor relative to matched non-tumor tissue, and previous functional studies demonstrated tumor recognition by Cluster-A members. In a focused analysis of a pancreatic cancer case, Cluster-A CD8 + T cells were selectively detected in tumor tissue, preferentially localized near malignant epithelial cells, and displayed an antigen-experienced effector-memory phenotype with prominent expression of granzymes A and K (GZMA/GZMK). Importantly, in another PDAC case that lacked Cluster-A clonotypes, these features extended to independent clonotypes, revealing a continuous tumor-association axis in which increasing T/N ratios were associated with progressively closer localization to malignant cells and increased GZMA/GZMK expression. Thus, repertoire enrichment, spatial tumor proximity, and effector-associated transcriptional states converged across independent tumor-enriched clonotypes. Outlook: These findings support the T/N ratio as a robust primary criterion for identifying candidate tumor-reactive TCRs. Integration of single-cell and spatial transcriptomics provides supporting biological evidence of tumor association and a framework for prioritizing therapeutic TCR candidates when functional validation is limited.
- Open Access
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Figure S6 shows copy number dynamics in EGFR-amplified glioblastoma samples
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Figure S6 shows copy number dynamics in EGFR-amplified glioblastoma samples
- Open Access
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Figure S1 characterises the MYCN amplification status, copy number heterogeneity and growth behaviour in neuroblastoma samples
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Figure S1 characterises the MYCN amplification status, copy number heterogeneity and growth behaviour in neuroblastoma samples
- Open Access
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Table S4 contains information about the MYCN status of neuroblastoma patient samples used in Figure 1 and Supplementary Figure 1
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Table S4 contains information about the MYCN status of neuroblastoma patient samples used in Figure 1 and Supplementary Figure 1
- Open Access
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Figure S2 shows simulation results of clonogenic assays under copy number-dependent and -independent cell fitness
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Figure S2 shows simulation results of clonogenic assays under copy number-dependent and -independent cell fitness
- Open Access
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Figure S3 demonstrates how MYC(N) dosage differences drive phenotypic heterogeneity in ecDNA-containing cancers
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Figure S3 demonstrates how MYC(N) dosage differences drive phenotypic heterogeneity in ecDNA-containing cancers
- Open Access
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Table S1 contains FISH proteomics datasets
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Table S1 contains FISH proteomics datasets
- Open Access
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Figure S4 provides computational and experimental models of ecDNA-dependent treatment responses in neuroblastoma
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Figure S4 provides computational and experimental models of ecDNA-dependent treatment responses in neuroblastoma
- Open Access
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Table S2 lists the GDCS compounds used in Supplementary Figure S4L
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Table S2 lists the GDCS compounds used in Supplementary Figure S4L
- Open Access
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Figure S8 illustrates how one-two punch, senolytic therapies can be used to target tumor cells with low MYCN copy numbers
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers
Supplementary Figure S8 illustrates how one-two punch, senolytic therapies can be used to target tumor cells with low MYCN copy numbers